Pegfilgrastim Biosimilar Market Opportunities

Pegfilgrastim Biosimilar Market to exhibit a CAGR of 10% through 2026 | Coherus Biosciences, Mylan N.V., Biocon

2021-03-23 // 0 Comments

Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required [read full press release…]

Home | Submit Press Release | Nationwide / EPR Network | Free Press Release Distribution | Real Time Press Release Distribution | Travel PR News | EuropaWire
© 2004-2024 Express-Press-Release.Net. Owned by EPR Network LLC. All Rights Reserved. All trade marks and names are owned by their respective owners.
RSS | Privacy | Disclaimer | TOS | Feedback
EPR Network LLC disclaims any content found in press releases published on its network - full disclaimer. Powered by WP. Theme by MH Themes
In the works: Consolidated Press Release Distribution | Social Press Release | Early Bird Press Release